Developing life-changing therapies for complex neurological disorders with axonal dysfunction

Therapeutic Focus

Toward a Cure for neuromuscular and neurodegenerative disorders

We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral nerve disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.

We are developing novel therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential applications in other complex neurological disorders.

Learn more about our therapeutic focus


We currently have three programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in preclinical development; our second program focusing on brain penetrant and selective HDAC6i is advancing into lead optimization, and our third program targeting subtype-selective GABABR1A activators for CMT1 is currently at the discovery stage.

About Us

Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.

The company is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and in the collaboration between the VIB labs of Joris de Wit and Bart De Strooper.

Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.

More about us

Gerhard Koenig, PhD - Chairman, Non Executive Director
Ward Capoen, PhD - Director
Bart Geers, PhD - Director
Alain Huriez, MD - Director
Bart De Taeye, PhD - Director
Jérôme Van Biervliet, PhD - Director
Sylvain Celanire, PhD - CEO & Director

Board of directors

Gerhard Koenig is a senior R&D leader with more than 28 years of experience in drug development

Board of directors

Ward Capoen is a Partner at V-Bio Ventures, which he joined in 2016

Board of directors

Bart Geers works as the investment manager for KULeuven Research & Development (LRD)

Board of directors

Alain Huriez brings over 30 years of experience in life sciences and finance

Board of directors

Bart De Taeye is Senior Investment Manager in the Life Sciences & Care team at PMV

Board of directors

Jérôme Van Biervliet is Managing Director of VIB

Board of directors

Sylvain Celanire has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector

All our team members | soon production